No Data
Percheron Therapeutics Proposes to In-license New Drug Program for Rare Neurological Disease
Percheron Therapeutics Ltd: Letter From The Chair and Half Year Accounts
Percheron Therapeutics Expects Partnering Proposals This Month After Rapid Progress in Discussions | ASX:PER, OTC:PERCF
ASX Small-Cap Stocks to Watch
Percheron Therapeutics Regroups After Clinical Trial Results; Vows to Continue to Conserve Cash and Develop Pipeline | ASX:PER, OTC:PERCF
Percheron Therapeutics Downgraded to Speculative Hold From Buy by Bell Potter